ABBV
Price
$194.94
Change
+$4.32 (+2.27%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
322.43B
21 days until earnings call
AZN
Price
$71.82
Change
+$1.00 (+1.41%)
Updated
Jul 10, 04:59 PM (EDT)
Capitalization
208.98B
19 days until earnings call
Interact to see
Advertisement

ABBV vs AZN

Header iconABBV vs AZN Comparison
Open Charts ABBV vs AZNBanner chart's image
ABBVIE
Price$194.94
Change+$4.32 (+2.27%)
Volume$49.2K
Capitalization322.43B
AstraZeneca
Price$71.82
Change+$1.00 (+1.41%)
Volume$56.28K
Capitalization208.98B
ABBV vs AZN Comparison Chart in %
Loading...
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABBV vs. AZN commentary
Jul 10, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Buy and AZN is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 10, 2025
Stock price -- (ABBV: $190.62 vs. AZN: $70.82)
Brand notoriety: ABBV and AZN are both notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ABBV: 83% vs. AZN: 86%
Market capitalization -- ABBV: $322.43B vs. AZN: $208.98B
ABBV [@Pharmaceuticals: Major] is valued at $322.43B. AZN’s [@Pharmaceuticals: Major] market capitalization is $208.98B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABBV’s FA Score shows that 3 FA rating(s) are green whileAZN’s FA Score has 1 green FA rating(s).

  • ABBV’s FA Score: 3 green, 2 red.
  • AZN’s FA Score: 1 green, 4 red.
According to our system of comparison, both ABBV and AZN are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABBV’s TA Score shows that 7 TA indicator(s) are bullish while AZN’s TA Score has 6 bullish TA indicator(s).

  • ABBV’s TA Score: 7 bullish, 2 bearish.
  • AZN’s TA Score: 6 bullish, 5 bearish.
According to our system of comparison, ABBV is a better buy in the short-term than AZN.

Price Growth

ABBV (@Pharmaceuticals: Major) experienced а -0.07% price change this week, while AZN (@Pharmaceuticals: Major) price change was -0.44% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.89%. For the same industry, the average monthly price growth was +0.62%, and the average quarterly price growth was +10.51%.

Reported Earning Dates

ABBV is expected to report earnings on Oct 24, 2025.

AZN is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.89% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABBV($322B) has a higher market cap than AZN($209B). ABBV has higher P/E ratio than AZN: ABBV (66.46) vs AZN (35.30). AZN (9.633) and ABBV (9.283) have similar YTD gains . ABBV has higher annual earnings (EBITDA): 17.2B vs. AZN (13.4B). ABBV has more cash in the bank: 12.8B vs. AZN (5.86B). AZN has less debt than ABBV: AZN (28.6B) vs ABBV (59.4B). ABBV has higher revenues than AZN: ABBV (54.3B) vs AZN (45.8B).
ABBVAZNABBV / AZN
Capitalization322B209B154%
EBITDA17.2B13.4B128%
Gain YTD9.2839.63396%
P/E Ratio66.4635.30188%
Revenue54.3B45.8B119%
Total Cash12.8B5.86B218%
Total Debt59.4B28.6B208%
FUNDAMENTALS RATINGS
ABBV vs AZN: Fundamental Ratings
ABBV
AZN
OUTLOOK RATING
1..100
5864
VALUATION
overvalued / fair valued / undervalued
1..100
86
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
1240
SMR RATING
1..100
1446
PRICE GROWTH RATING
1..100
5259
P/E GROWTH RATING
1..100
1483
SEASONALITY SCORE
1..100
850

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AZN's Valuation (24) in the Pharmaceuticals Major industry is somewhat better than the same rating for ABBV (86). This means that AZN’s stock grew somewhat faster than ABBV’s over the last 12 months.

ABBV's Profit vs Risk Rating (12) in the Pharmaceuticals Major industry is in the same range as AZN (40). This means that ABBV’s stock grew similarly to AZN’s over the last 12 months.

ABBV's SMR Rating (14) in the Pharmaceuticals Major industry is in the same range as AZN (46). This means that ABBV’s stock grew similarly to AZN’s over the last 12 months.

ABBV's Price Growth Rating (52) in the Pharmaceuticals Major industry is in the same range as AZN (59). This means that ABBV’s stock grew similarly to AZN’s over the last 12 months.

ABBV's P/E Growth Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for AZN (83). This means that ABBV’s stock grew significantly faster than AZN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ABBVAZN
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
48%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
57%
Bullish Trend 2 days ago
65%
Momentum
ODDS (%)
Bullish Trend 2 days ago
62%
Bullish Trend 2 days ago
54%
MACD
ODDS (%)
Bullish Trend 2 days ago
50%
Bearish Trend 2 days ago
43%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
57%
Bearish Trend 2 days ago
46%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
60%
Bearish Trend 2 days ago
45%
Advances
ODDS (%)
Bullish Trend 2 days ago
56%
Bullish Trend 2 days ago
54%
Declines
ODDS (%)
Bearish Trend 4 days ago
46%
Bearish Trend 8 days ago
45%
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
40%
Aroon
ODDS (%)
Bullish Trend 2 days ago
53%
Bullish Trend 2 days ago
41%
View a ticker or compare two or three
Interact to see
Advertisement
ABBV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
AZN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
GNOM9.030.24
+2.75%
Global X Genomics & Biotechnology ETF
DFSI39.620.31
+0.78%
Dimensional International Sstby Cr 1 ETF
GLDM65.650.25
+0.38%
SPDR® Gold MiniShares
HYFI37.350.12
+0.32%
AB High Yield ETF
SIJ12.25-0.13
-1.03%
ProShares UltraShort Industrials